Specifically, CF@SNPs attenuated dry eye pathology by suppressing p53‐SLC7A11‐GSH‐dependent ferroptosis and TNF‐α‐associated inflammatory cascades, accompanied by favorable biocompatibility. The gene discussed is TP53; the disease is dry eye syndrome.